Cargando…
Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling
The EphA2 receptor tyrosine kinase activates signaling pathways with different, and sometimes opposite, effects in cancer and other pathologies. Thus, highly specific and potent biased ligands that differentially control EphA2 signaling responses could be therapeutically valuable. Here, we use EphA2...
Autores principales: | Gomez-Soler, Maricel, Gehring, Marina P., Lechtenberg, Bernhard C., Zapata-Mercado, Elmer, Ruelos, Alyssa, Matsumoto, Mike W., Hristova, Kalina, Pasquale, Elena B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858996/ https://www.ncbi.nlm.nih.gov/pubmed/35243233 http://dx.doi.org/10.1016/j.isci.2022.103870 |
Ejemplares similares
-
A cancer mutation promotes EphA4 oligomerization and signaling by altering the conformation of the SAM domain
por: Light, Taylor P., et al.
Publicado: (2021) -
The efficacy of receptor tyrosine kinase EphA2 autophosphorylation increases with EphA2 oligomer size
por: Zapata-Mercado, Elmer, et al.
Publicado: (2022) -
Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker
por: Lechtenberg, Bernhard C., et al.
Publicado: (2021) -
Unliganded EphA3 dimerization promoted by the SAM domain
por: Singh, Deo R., et al.
Publicado: (2015) -
The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures
por: Singh, Deo R., et al.
Publicado: (2018)